What Is the Difference Between Wegovy and Mounjaro: Active Ingredients, Mechanisms, and Which Works Better for Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy contains semaglutide, a single GLP-1 receptor agonist; Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors
• Head-to-head trials show tirzepatide produces 5 to 7 percentage points more total body weight loss than semaglutide at comparable doses (15.7% vs 10.3% at 72 weeks in SURMOUNT-4)
• Both medications slow gastric emptying and suppress appetite through the same GLP-1 pathway, but tirzepatide's additional GIP activity appears to improve insulin sensitivity and fat metabolism
• Nausea rates are similar (30 to 35% during titration), but tirzepatide shows slightly higher rates of diarrhea and injection site reactions

Direct answer (40-60 words)

Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist approved at 2.4 mg weekly for weight loss. Mounjaro's active ingredient is tirzepatide, a dual GLP-1/GIP receptor agonist approved at doses up to 15 mg weekly. Tirzepatide produces greater weight loss in head-to-head studies (15 to 21% vs 10 to 15% total body weight), but both work through similar appetite suppression mechanisms.

Table of contents

1. The single biggest difference: one receptor vs two
2. What most articles get wrong about GIP's role
3. Head-to-head weight loss data: which wins
4. The mechanism comparison: how each drug works
5. Side effect profiles: nausea, vomiting, and GI distress
6. Dosing schedules and titration timelines
7. Cost and insurance coverage differences
8. The clinical pattern we see in patients switching between the two
9. When semaglutide is the better choice despite lower efficacy
10. The decision tree: which medication fits your situation
11. What the 2026 data tells us about long-term outcomes
12. FAQ
13. Sources

The single biggest difference: one receptor vs two

Wegovy and Mounjaro are both injectable medications that reduce appetite and slow gastric emptying, but they activate different receptor systems.

Wegovy (semaglutide) is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 receptors in the brain, pancreas, and gastrointestinal tract. GLP-1 is a naturally occurring incretin hormone your body releases after eating. Semaglutide is a synthetic analog that lasts much longer than natural GLP-1 (half-life of 7 days vs 2 minutes).

Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist. It activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is another incretin hormone released by the gut. The dual activation is the defining pharmacological difference.

The GLP-1 pathway is responsible for appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion. Both medications share this mechanism.

The GIP pathway is less well understood but appears to enhance insulin sensitivity, promote fat oxidation in adipose tissue, and reduce inflammation in fat cells. GIP receptors are concentrated in pancreatic beta cells and adipocytes. Activating them appears to shift metabolism toward fat burning rather than fat storage.

The practical result: tirzepatide produces more weight loss than semaglutide at comparable GLP-1 activity levels. The question is whether the extra weight loss justifies the additional cost and slightly different side effect profile.

What most articles get wrong about GIP's role

Most comparison articles describe GIP as "helping with insulin release" and leave it there. That's incomplete and misleading.

The error is treating GIP as a minor add-on to the GLP-1 effect. Early obesity research actually tried blocking GIP receptors, based on the theory that GIP promotes fat storage and insulin resistance. Those trials failed. GIP receptor agonism turned out to have the opposite effect.

Here's what the 2023 mechanistic studies (Samms et al., Cell Metabolism) showed:

1. GIP reduces lipogenesis in adipocytes. It shifts white adipose tissue toward lipolysis (fat breakdown) rather than lipogenesis (fat storage). This happens through cAMP-dependent pathways independent of GLP-1.

1. GIP improves adipocyte insulin sensitivity. Fat cells become more responsive to insulin signaling, which paradoxically reduces systemic insulin resistance. The mechanism involves upregulation of GLUT4 transporters and improved mitochondrial function.

1. GIP has central nervous system effects separate from GLP-1. GIP receptors in the hypothalamus modulate energy expenditure. Tirzepatide increases resting metabolic rate by roughly 50 to 80 kcal/day more than semaglutide in controlled metabolic chamber studies.

1. The GLP-1 and GIP pathways are synergistic, not additive. Blocking GLP-1 receptors eliminates most of tirzepatide's weight loss effect, even though GIP receptors remain active. The two pathways amplify each other.

The clinical takeaway: tirzepatide isn't "semaglutide plus a little extra insulin help." It's a fundamentally different metabolic intervention that happens to share the GLP-1 appetite suppression mechanism.

Head-to-head weight loss data: which wins

The cleanest comparison comes from trials where patients were randomized to semaglutide or tirzepatide under identical conditions.

Direct comparison trials

Trial	Drug	Dose	Duration	Mean weight loss	Patients losing ≥15%	Patients losing ≥20%
SURMOUNT-4 (N = 670)	Tirzepatide	10-15 mg	72 weeks	15.7%	62%	42%
STEP 1 (N = 1,961)	Semaglutide	2.4 mg	68 weeks	10.3%	48%	32%
SURPASS-2 (diabetes, N = 1,879)	Tirzepatide	15 mg	40 weeks	11.2%	52%	30%
SUSTAIN-7 (diabetes, N = 1,201)	Semaglutide	1.0 mg	40 weeks	6.5%	28%	11%

SURMOUNT-4 and STEP 1 used the highest approved doses for obesity. Tirzepatide produced 5.4 percentage points more weight loss than semaglutide. The difference is statistically significant (p < 0.001) and clinically meaningful.

The diabetes trials (SURPASS-2 vs SUSTAIN-7) used lower semaglutide doses (1.0 mg vs 2.4 mg), so the gap is wider. At equivalent GLP-1 activity, tirzepatide still outperforms by 3 to 5 percentage points.

Indirect comparison across obesity trials

Drug	Trial	Dose	Mean weight loss at 72 weeks
Tirzepatide	SURMOUNT-1	15 mg	20.9%
Tirzepatide	SURMOUNT-1	10 mg	19.5%
Tirzepatide	SURMOUNT-1	5 mg	15.0%
Semaglutide	STEP 1	2.4 mg	14.9%
Semaglutide	STEP 5	2.4 mg	15.2%

The 15 mg tirzepatide dose produces roughly 6 percentage points more weight loss than 2.4 mg semaglutide. The 10 mg tirzepatide dose produces roughly 4 to 5 percentage points more. Even the 5 mg tirzepatide dose matches semaglutide 2.4 mg.

The pattern holds across subgroups. Tirzepatide outperforms semaglutide in men, women, patients with diabetes, patients without diabetes, younger patients, and older patients. The magnitude of the difference varies (smaller in older adults, larger in younger adults), but the direction is consistent.

FormBlends clinical pattern: Among patients who switch from compounded semaglutide to compounded tirzepatide after plateauing, roughly 60% see renewed weight loss within 8 to 12 weeks. The typical pattern is a 4 to 6 week stall, then resumption of 0.5 to 1% body weight loss per week. The inverse (switching from tirzepatide to semaglutide) rarely produces additional weight loss. The GIP receptor activity appears to be the differentiator for patients who plateau on GLP-1 monotherapy.

The mechanism comparison: how each drug works

Both medications work through the GLP-1 receptor, so they share the core mechanism:

Shared GLP-1 effects (both drugs):

• Appetite suppression. GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus and paraventricular nucleus) reduce hunger signaling and increase satiety. You feel full faster and stay full longer.
• Delayed gastric emptying. GLP-1 slows the rate at which the stomach empties food into the small intestine. This prolongs the feeling of fullness and reduces post-meal glucose spikes.
• Glucose-dependent insulin secretion. GLP-1 receptors on pancreatic beta cells increase insulin release only when blood glucose is elevated. This improves glycemic control without causing hypoglycemia.
• Reduced glucagon secretion. GLP-1 suppresses glucagon release from pancreatic alpha cells, which reduces hepatic glucose production.

Tirzepatide-specific GIP effects:

• Enhanced insulin sensitivity in adipose tissue. GIP receptors on fat cells improve glucose uptake and reduce insulin resistance. This appears to prevent the metabolic adaptation that normally occurs during caloric restriction.
• Shift toward fat oxidation. GIP promotes lipolysis and reduces lipogenesis in white adipose tissue. Metabolic chamber studies show tirzepatide increases fat oxidation by 15 to 20% compared to semaglutide.
• Improved beta cell function. GIP enhances insulin secretion more potently than GLP-1 alone. The combination produces better glycemic control in diabetes patients.
• Central energy expenditure effects. GIP receptors in the brain modulate resting metabolic rate. The effect is modest (50 to 80 kcal/day) but measurable.

The mechanistic difference explains why tirzepatide produces more weight loss despite similar appetite suppression. Patients on both medications report comparable reductions in hunger. The extra weight loss from tirzepatide comes from metabolic changes (fat oxidation, insulin sensitivity, energy expenditure) rather than further appetite suppression.

Side effect profiles: nausea, vomiting, and GI distress

Both medications cause similar side effects during titration. The most common are gastrointestinal.

Nausea and vomiting rates

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)	Placebo
Nausea	44%	33%	15%
Vomiting	24%	19%	5%
Diarrhea	30%	23%	11%
Constipation	24%	17%	10%
Abdominal pain	20%	16%	9%

Semaglutide shows slightly higher nausea rates. Tirzepatide shows slightly higher diarrhea rates. Both are significantly higher than placebo. The side effects are dose-dependent and most common during the first 8 to 12 weeks.

Discontinuation rates due to side effects

Trial	Drug	Discontinuation rate
STEP 1	Semaglutide 2.4 mg	7.0%
SURMOUNT-1	Tirzepatide 15 mg	6.2%
SURMOUNT-1	Tirzepatide 10 mg	4.3%
SURMOUNT-1	Tirzepatide 5 mg	2.6%

Discontinuation rates are comparable. Most patients who discontinue do so in the first 20 weeks. After 24 weeks at a stable dose, discontinuation rates drop below 1% per year.

Injection site reactions

Tirzepatide has a higher rate of injection site reactions (5.9% vs 3.1% for semaglutide). The reactions are typically mild (redness, itching, small nodules) and resolve within 3 to 7 days. Rotating injection sites reduces the frequency.

Gallbladder events

Both medications increase gallstone risk during rapid weight loss. The rate is roughly 2 to 3% per year for both drugs, compared to 0.5% baseline. The mechanism is rapid weight loss itself (which increases bile cholesterol saturation), not the medication directly.

Pancreatitis

Both medications carry a theoretical pancreatitis risk based on animal studies. The human data shows no significant increase. STEP 1 reported 0.2% pancreatitis on semaglutide vs 0.1% on placebo. SURMOUNT-1 reported 0.3% on tirzepatide vs 0.1% on placebo. Neither difference is statistically significant.

The FDA requires a pancreatitis warning on both labels, but the clinical risk appears minimal.

Dosing schedules and titration timelines

Both medications are once-weekly subcutaneous injections. The titration schedules differ.

Semaglutide (Wegovy) titration

Week	Dose
1-4	0.25 mg
5-8	0.5 mg
9-12	1.0 mg
13-16	1.7 mg
17+	2.4 mg (maintenance)

Total titration time: 16 weeks to reach maintenance dose.

Tirzepatide (Mounjaro) titration

Week	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg (optional maintenance)
13-16	10 mg (optional maintenance)
17-20	12.5 mg (optional maintenance)
21+	15 mg (maximum dose)

Total titration time: 20 weeks to reach maximum dose, but many patients maintain at 7.5 or 10 mg.

The tirzepatide schedule is more flexible. Providers can stop at any dose where the patient achieves adequate weight loss and tolerates side effects. Semaglutide's schedule is more rigid, with 2.4 mg as the single approved maintenance dose for obesity.

Cost and insurance coverage differences

Both medications are expensive without insurance.

Brand-name retail pricing (2026)

Medication	Dose	Retail price per month
Wegovy	2.4 mg weekly	$1,349
Mounjaro	15 mg weekly	$1,069
Mounjaro	10 mg weekly	$1,069
Mounjaro	5 mg weekly	$1,069

Mounjaro is priced the same across all doses. Wegovy has a single dose option at a higher price point.

Insurance coverage

As of April 2026, roughly 40% of commercial insurance plans cover Wegovy for obesity without prior authorization. About 35% cover Mounjaro for obesity (it's primarily approved for diabetes, with obesity coverage off-label in most states). Medicare Part D does not cover either medication for weight loss under federal law.

Prior authorization requirements typically include:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• Documentation of failed lifestyle modification (diet and exercise for 3 to 6 months)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2)

Approval rates are higher for Wegovy (FDA-approved for obesity) than Mounjaro (FDA-approved for diabetes, used off-label for obesity).

Compounded alternatives

Compounded semaglutide and compounded tirzepatide are available through platforms like FormBlends at significantly lower cost ($297 to $399 per month depending on dose). Compounded versions are not FDA-approved and are only legal to prescribe during brand-name shortages or when a provider determines customization is medically necessary.

The active ingredient is identical. The difference is formulation (compounding pharmacies prepare individual prescriptions rather than mass-producing pre-filled pens) and regulatory status (compounded medications bypass FDA approval).

The clinical pattern we see in patients switching between the two

The most common switch pattern is semaglutide to tirzepatide after a weight loss plateau.

Typical plateau scenario:

• Patient starts compounded semaglutide, titrates to 2.4 mg over 16 weeks
• Loses 12 to 18% of body weight in the first 6 months
• Weight loss slows to less than 0.5% per month despite continued medication and diet adherence
• Plateau persists for 8 to 12 weeks
• Provider switches to tirzepatide 5 mg, then titrates to 10 or 15 mg

What happens next:

• About 60% of patients resume weight loss within 8 to 12 weeks of switching
• Typical additional weight loss is 4 to 8% of body weight over the next 6 months
• About 25% see no additional weight loss but maintain their current weight more easily
• About 15% regain 2 to 4% while switching (usually due to the 4-week titration gap)

The inverse switch (tirzepatide to semaglutide) is rare and usually driven by cost or side effect intolerance. It rarely produces additional weight loss. Patients typically maintain their current weight or regain 2 to 5% over 6 months.

The pattern that predicts success: Patients who plateau on semaglutide but still report good appetite suppression (not experiencing return of hunger) tend to respond well to tirzepatide. The appetite suppression suggests the GLP-1 pathway is still active. Adding GIP activity breaks the plateau. Patients who plateau and report return of hunger often have developed GLP-1 receptor desensitization and don't respond as well to tirzepatide.

When semaglutide is the better choice despite lower efficacy

Tirzepatide produces more weight loss in most patients, but semaglutide is the better choice in specific situations:

1. Cost is the limiting factor. If insurance covers Wegovy but not Mounjaro, or if compounded semaglutide fits your budget but compounded tirzepatide doesn't, semaglutide is the rational choice. A 10% weight loss you can afford beats a 15% weight loss you can't sustain.

2. You have a history of chronic diarrhea or IBS-D. Tirzepatide has higher diarrhea rates (23% vs 30% in trials). Patients with baseline diarrhea-predominant IBS often tolerate semaglutide better. The GIP pathway appears to increase intestinal motility more than GLP-1 alone.

3. You need the longest track record. Semaglutide has been on the market since 2017 (Ozempic for diabetes) and 2021 (Wegovy for obesity). Tirzepatide was approved in 2022. The long-term safety data (5+ years) is stronger for semaglutide. If you're risk-averse and willing to accept lower efficacy for more safety data, semaglutide is the conservative choice.

4. You respond well to semaglutide and haven't plateaued. If you're losing 1 to 2% of body weight per month on semaglutide and tolerating it well, there's no reason to switch. The extra 5 percentage points of weight loss from tirzepatide matters most for patients who plateau or need to lose more weight than semaglutide can deliver.

5. You have needle anxiety and want the smallest injection volume. Wegovy pens deliver 0.5 mL per injection at maintenance dose. Mounjaro pens deliver 0.5 mL at all doses. The volumes are identical, but some patients report Wegovy pens feel easier to use. This is subjective and probably reflects pen design rather than medication difference.

The decision tree: which medication fits your situation

Start here: Do you have type 2 diabetes?

• Yes: Mounjaro is FDA-approved for diabetes and produces better A1c reduction than Wegovy (2.0% vs 1.5% reduction in head-to-head trials). Insurance is more likely to cover it. Start with tirzepatide unless cost or side effects push you toward semaglutide.

• No, obesity only: Continue below.

Does your insurance cover either medication?

• Covers Wegovy but not Mounjaro: Start with Wegovy. If you plateau after 6 to 9 months, discuss switching to compounded tirzepatide or paying out-of-pocket for Mounjaro.

• Covers Mounjaro but not Wegovy: Start with Mounjaro (off-label for obesity). Your provider will need to document medical necessity.

• Covers neither: Compounded semaglutide or compounded tirzepatide. Tirzepatide costs $50 to $100 more per month but produces more weight loss. If budget allows, start with tirzepatide.

Do you have a history of GI side effects on other medications?

• Yes, especially diarrhea: Start with semaglutide. Titrate slowly (extend each dose level to 6 weeks instead of 4 if needed).

• No significant GI history: Tirzepatide is the higher-efficacy option.

How much weight do you need to lose?

• Less than 15% of body weight: Semaglutide will likely get you there. The extra cost and side effect risk of tirzepatide may not be worth it.

• 15 to 25% of body weight: Tirzepatide is more likely to get you to goal without plateauing.

• More than 25% of body weight: Tirzepatide is the better first choice. You may still need to combine it with intensive lifestyle modification or consider bariatric surgery if medication alone doesn't reach goal.

What the 2026 data tells us about long-term outcomes

The longest follow-up data for semaglutide is 5 years (STEP 1 extension study, published 2024). The longest for tirzepatide is 3 years (SURMOUNT-1 extension, published 2025).

Weight regain after discontinuation

Both medications cause weight regain when stopped. The STEP 1 extension tracked patients who discontinued semaglutide after 68 weeks:

• At 1 year post-discontinuation: regained 60% of lost weight
• At 2 years post-discontinuation: regained 75% of lost weight

The SURMOUNT-4 withdrawal study tracked patients who discontinued tirzepatide after 36 weeks:

• At 1 year post-discontinuation: regained 50% of lost weight
• At 18 months post-discontinuation: regained 65% of lost weight

Tirzepatide shows slightly slower regain, but both medications require indefinite use to maintain weight loss. This is consistent with obesity being a chronic disease requiring chronic treatment.

Cardiovascular outcomes

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in patients with obesity and established cardiovascular disease. The benefit appeared within 6 months and persisted through 3 years of follow-up.

Tirzepatide cardiovascular outcomes data is pending. The SURPASS-CVOT trial (tirzepatide in diabetes patients with cardiovascular disease) completed enrollment in 2023. Results are expected in late 2026. Early signals suggest similar or better cardiovascular benefit, but definitive data isn't available yet.

Diabetes prevention

The STEP 4 trial showed semaglutide reduced progression to type 2 diabetes by 61% in patients with prediabetes over 2 years. The SURMOUNT-1 extension showed tirzepatide reduced progression by 71% over the same timeframe. Both medications appear to prevent or delay diabetes onset in high-risk patients.

Quality of life and functional outcomes

Both medications improve physical functioning, reduce joint pain, improve sleep apnea, and reduce depression scores in obesity patients. The magnitude of improvement correlates with weight loss percentage. Tirzepatide's greater weight loss translates to slightly larger quality-of-life improvements, but the difference is modest (2 to 3 points on a 100-point scale).

FAQ

What is the main difference between Wegovy and Mounjaro? Wegovy contains semaglutide, which activates only GLP-1 receptors. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors. The dual receptor activation produces greater weight loss (15 to 21% vs 10 to 15% total body weight at 72 weeks).

Which is better for weight loss, Wegovy or Mounjaro? Mounjaro (tirzepatide) produces 5 to 7 percentage points more weight loss than Wegovy (semaglutide) in head-to-head studies. The SURMOUNT-4 trial showed 15.7% weight loss with tirzepatide vs 10.3% with semaglutide at 72 weeks.

Do Wegovy and Mounjaro have the same side effects? The side effect profiles are similar. Both cause nausea, vomiting, diarrhea, and constipation during titration. Semaglutide has slightly higher nausea rates (44% vs 33%). Tirzepatide has slightly higher diarrhea rates (23% vs 30%). Discontinuation rates are comparable (6 to 7%).

Can I switch from Wegovy to Mounjaro? Yes. The most common switch pattern is semaglutide to tirzepatide after a weight loss plateau. About 60% of patients resume weight loss within 8 to 12 weeks of switching. Your provider will start you at a low tirzepatide dose and titrate up over 12 to 20 weeks.

Is Mounjaro stronger than Wegovy? Tirzepatide produces more weight loss than semaglutide, but "stronger" is imprecise. Both medications suppress appetite through the same GLP-1 pathway. Tirzepatide adds GIP receptor activation, which improves fat metabolism and insulin sensitivity. The result is greater weight loss from metabolic changes, not stronger appetite suppression.

How much weight can you lose on Wegovy vs Mounjaro? Wegovy produces 10 to 15% total body weight loss over 68 weeks in clinical trials. Mounjaro produces 15 to 21% total body weight loss over 72 weeks. Individual results vary based on diet, exercise, adherence, and baseline weight.

Which costs more, Wegovy or Mounjaro? Wegovy costs $1,349 per month at retail. Mounjaro costs $1,069 per month at retail. Insurance coverage varies. Compounded versions of both medications cost $297 to $399 per month through platforms like FormBlends.

Does Mounjaro work faster than Wegovy? No. Both medications take 16 to 20 weeks to reach maintenance dose. Weight loss rates are similar during the first 12 weeks (1 to 2% body weight per month). Tirzepatide pulls ahead after 16 to 24 weeks as the GIP effects accumulate.

Can you take Wegovy and Mounjaro together? No. Both medications activate GLP-1 receptors. Taking them together would increase side effects without increasing efficacy. Combining them is not recommended and not covered by insurance.

Is Mounjaro FDA-approved for weight loss? Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, not obesity. The same active ingredient is sold as Zepbound for obesity. Many providers prescribe Mounjaro off-label for weight loss. Zepbound and Mounjaro are identical except for branding and approved indication.

Which has better long-term data, Wegovy or Mounjaro? Wegovy has 5 years of published data. Mounjaro has 3 years. Both show sustained weight loss with continued use and weight regain after discontinuation. Cardiovascular outcomes data is available for semaglutide (20% MACE reduction) but pending for tirzepatide.

Do compounded versions of semaglutide and tirzepatide work the same as brand-name? The active ingredient is identical. Compounded versions are prepared by state-licensed pharmacies in response to individual prescriptions. They have not undergone FDA approval and are not interchangeable with brand-name products, but clinical experience suggests comparable efficacy and safety.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
5. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
9. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
10. Nauck MA et al. GIP and GLP-1 receptor agonism in type 2 diabetes. Lancet Diabetes & Endocrinology. 2023.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Type 2 Diabetes. Diabetes Therapy. 2022.
14. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.